Block the pain. Reduce the risk.

Warning: May be habit forming.

Reprexain® (hydrocodone bitartrate 5 mg and ibuprofen
200 mg tablets) is indicated for the short-term (generally
less than 10 days) management of acute pain.

Reprexain® is not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis.

Reprexain® – Dual Analgesic Action Without Liver Toxicity Risk1

• Reprexain® contains no acetaminophen
• Acetaminophen is the most common drug associated with intentional and accidental hepatoxicity2,3
• Percentage of fatal acute liver failures caused by acetaminophen increased by nearly 30% within a five-year time period3
• Hydrocodone and ibuprofen do not include Constitutive Androstane Receptor (CAR), which has been shown to regulate liver toxicity1

Reprexain® combines two analgesics and works in two ways

• Ibuprofen's central analgesic action reduces inflammation and pain and demonstrates greater efficacy than acetaminophen4
• Hydrocodone blocks pain impulse generation and is about six times more potent than codeine5

Reprexain® – Combination Offers Significant Relief

Reprexain's NSAID/Opiate Combination

• Has been shown to significantly reduce pain compared to either ingredient alone or placebo7,8
• Has a well-established safety profile9
• Provides physicians prescription-dosing convenience for class three drugs

Effect of Hydrocodone / lbuprofen Combination*

Comparative pain-relief scores of hydrocodone/ibuprofen combination, hydrocodone, ibuprofen, and placebo in a single-dose study of patients with moderate to severe postoperative pain (N=240)7

 

Safety Information

Reprexain is indicated for the short-term (generally less than 10 days) management of acute pain. It is not indicated for the treatment of conditions such as osteoarthritis or rheumatoid arthritis. Reprexain should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Serious gastrointestinal toxicity, such as inflammation, bleeding, ulceration and perforation of the stomach, small intestine, or large intestine, with or without warning symptoms, can occur in patients taking NSAIDs. All NSAIDs have been associated with an increase in cardiovascular adverse events. The most commonly reported side effects with Reprexain include headache, somnolence, constipation, nausea, dizziness, and dyspepsia. Hydrocodone may impair mental and/or physical abilities when ingested with alcohol and other CNS depressants.

Prescribing Information

For complete Prescribing Information click here.

References:

1. Zang, W. Huang, S. S. Chua, P. Wei, D. D. Moore, Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002;298:422-424.
2. Farell, SE. Toxicity, Acetaminophen. eMedicine. Last updated December 12, 2006. Accessed www.emedicine.com/emerg/topics819.htm
3. Larson AM, Polson J. Fontana RJ, et. al. Acetaminophen-Induced Acute Liver Failure: Results of a United States Multicenter. Prospective Study. Hepatology; December 2005.
4. Sachs CJ. Oral analgesics for acute nonspecific pain. Am Fam Physician. 2005;715.
5. Sunshine, et al. Analgesic efficacy of a hydrocodone with ibuprofen combination compared with ibuprofen alone for the treatment of acute postoperative pain. J Clin Pharmacol. 37 (10): 908.
6. Kimball, JW. Online Biology. Last updated 4/30/07. Accessed http://users.rcn.com/jkimball.ma.ultranet/biologypages.
7. Wideman GL, Keffer M, Morris E, et al. Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain. Clin Pharmacol Ther. 1999;65:66-76.
8. Betancourt JW. Efficacy of ibuprofen-hydrocodone for the treatment of postoperative pain after periodontal surgery. J Periodontology. 2004;75:872-876.
9. See Full Package Insert.

By Prescription Only.